← BioNTech overview

BioNTech vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioNTech SE (BNTX)

Q3 2026
▼2▲1

BioNTech's cancer pipeline advances but COVID collapse and trial setback weigh

  • Cancer pipeline progress BioNTech's cancer pipeline gained traction: gotistobart showed strong Phase 3 lung cancer survival data, pumitamig advanced in kidney cancer, and Moderna/Merck's mRNA cancer vaccine success lifted sector sentiment.

    This is a key positive driver for the stock, showing pipeline potential.

  • COVID revenue collapse and guidance cut COVID revenue continues collapsing, forcing restructuring and a 2026 guidance cut to €1.6–1.9 billion, which pressures the company's financial outlook.

    This is a major negative factor affecting revenue and investor confidence.

  • Colorectal cancer trial halted BioNTech's own mRNA colorectal cancer trial was halted for futility and a survival imbalance, cutting shares and raising concerns about its pipeline.

    This is a significant setback that directly impacted the stock price.

  • Legal risks and leadership change Patent lawsuits from Arbutus/Roivant and Monsanto add legal risk, while a new CEO brings execution uncertainty and BMO downgraded the stock.

    These factors create uncertainty and negative sentiment, offsetting some positives.

September 2026
▲2▼2

Lung cancer win lifts BioNTech, but patent suit and downgrade weigh

  • Gotistobart nearly doubles lung cancer survival BioNTech and OncoC4 reported that gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial. This is the first strong sign that BioNTech's cancer pipeline can work, which supports the shares because investors have doubted the company's move beyond COVID vaccines.

    This is the period's biggest new positive and directly addresses doubts about BioNTech's cancer strategy.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected BioNTech's bid to dismiss Monsanto's patent lawsuit over mRNA technology used in COVID-19 vaccines. The case can now proceed, creating legal uncertainty and potential future costs or royalties, which weighs on the shares.

    This is a new legal risk that could affect BioNTech's finances and is not in earlier reports.

  • BMO downgrade and price target cut BMO downgraded BioNTech to market perform and cut its price target to $105 from $128, citing the failed colorectal cancer trial and lower revenue guidance. Analyst downgrades can push the shares down because they signal weaker confidence in future earnings.

    This is a new analyst action that directly affects investor sentiment and the stock's perceived value.

  • Health Canada approves XFG-adapted COMIRNATY Health Canada approved BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for people aged 6 months and older. This secures regulated seasonal revenue from Canada, helping offset weaker overall COVID demand and supporting the balance sheet.

    This is a new regulatory approval that adds a revenue stream and is not in earlier reports.

Latest
▲2▼2

Lung cancer win lifts BioNTech, but patent suit and downgrade weigh

  • Gotistobart nearly doubles lung cancer survival BioNTech and OncoC4 reported that gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial. This is the first strong sign that BioNTech's cancer pipeline can work, which supports the shares because investors have doubted the company's move beyond COVID vaccines.

    This is the period's biggest new positive and directly addresses doubts about BioNTech's cancer strategy.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected BioNTech's bid to dismiss Monsanto's patent lawsuit over mRNA technology used in COVID-19 vaccines. The case can now proceed, creating legal uncertainty and potential future costs or royalties, which weighs on the shares.

    This is a new legal risk that could affect BioNTech's finances and is not in earlier reports.

  • BMO downgrade and price target cut BMO downgraded BioNTech to market perform and cut its price target to $105 from $128, citing the failed colorectal cancer trial and lower revenue guidance. Analyst downgrades can push the shares down because they signal weaker confidence in future earnings.

    This is a new analyst action that directly affects investor sentiment and the stock's perceived value.

  • Health Canada approves XFG-adapted COMIRNATY Health Canada approved BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for people aged 6 months and older. This secures regulated seasonal revenue from Canada, helping offset weaker overall COVID demand and supporting the balance sheet.

    This is a new regulatory approval that adds a revenue stream and is not in earlier reports.

August 2026
▼2▲1

Cancer vaccine hopes clash with trial failure and weak guidance

  • Sector optimism from Moderna/Merck mRNA cancer vaccine success Moderna and Merck's Phase 3 mRNA cancer vaccine success lifted BioNTech shares about 22%, as investors bet the whole mRNA cancer field could win. BioNTech also reported promising first-in-class lung cancer data and won EU and FDA approvals for an updated COVID vaccine.

    This sector-wide rally and positive pipeline news were a major force pushing BioNTech shares up during the month.

  • Own mRNA colorectal cancer trial halted for futility and survival imbalance BioNTech's own Phase 2 mRNA colorectal cancer vaccine trial was stopped for futility and later for a survival imbalance, cutting shares 10% and then 7.5%. This directly undercut the optimism from the sector news and reminded investors that not all mRNA cancer bets will work.

    This was a major negative event that dragged BioNTech's stock down and highlighted pipeline risk.

  • 2026 revenue guidance cut on weak COVID demand BioNTech reduced its 2026 revenue guidance to €1.6–1.9 billion because COVID vaccine demand remains weak. This confirmed the company's main revenue source is still shrinking, adding pressure on the stock and raising doubts about near-term earnings.

    The guidance cut is a key negative driver that directly affects investor expectations for BioNTech's financial performance.

  • New CEO and strong cash cushion, but execution uncertainty BioNTech named a new CEO, creating strategic uncertainty, though it still holds €16.6 billion in cash. Upcoming ESMO data and a head-and-neck cancer interim analysis are key catalysts, but pipeline risk, rising competition, and execution challenges remain.

    This captures the mixed balance of a strong cash position and upcoming catalysts against leadership change and execution risks.

▼2▲1

BioNTech cuts guidance, replaces CEO, and halts a cancer vaccine trial

  • 2026 revenue guidance cut on weak COVID demand BioNTech lowered its 2026 revenue forecast to €1.6–1.9 billion from €2.0–2.3 billion, mainly because COVID-19 vaccine demand is weaker than expected. Less money coming in makes the shares less attractive, even though the company still holds €16.6 billion in cash.

    A direct cut to expected sales is a core reason the stock is under pressure.

  • New CEO named as company shifts focus Guido Oelkers will become CEO by February 1, replacing the current leadership. A new boss can bring fresh direction, but it also creates uncertainty about strategy and execution while BioNTech tries to move beyond COVID vaccines into cancer treatments.

    Leadership change is a major event that affects investor confidence and future strategy.

  • Colorectal cancer vaccine trial stopped for survival imbalance BioNTech ended a mid-stage trial of its personalized mRNA cancer vaccine in colorectal cancer after a monitoring committee saw a survival imbalance between groups. This raises doubts about the mRNA cancer strategy and sent shares down 7.5%, reminding investors that most cancer vaccine attempts still fail.

    The trial halt is a direct setback to the pipeline that investors hoped would drive future growth.

  • EU and FDA approvals for updated COVID vaccine European and U.S. regulators authorized BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for the fall season. This allows sales in 27 EU countries plus the U.S., providing some near-term revenue even as overall COVID demand softens.

    Regulatory approvals secure near-term sales and partially offset the weak demand outlook.

▲2▼1

mRNA cancer hopes lift BioNTech, then its own trial fails

  • Rival's mRNA cancer win lifts whole sector Moderna and Merck's Phase 3 mRNA cancer vaccine success in melanoma sent biotech stocks to post-pandemic highs and lifted BioNTech about 22%. Investors read it as proof that mRNA cancer treatments can work, which supports BioNTech's own pipeline value.

    This sector-wide read-across was the main force pushing BioNTech shares up during the period.

  • New lung cancer data shows pipeline progress BioNTech presented first-in-class lung cancer data combining pumitamig with a B7H3 antibody-drug conjugate at a major conference. It signals real progress beyond COVID vaccines, but the company is still unprofitable and depends on late-stage trials succeeding.

    It is a company-specific pipeline update that supports the growth story behind the stock.

  • Own mRNA cancer vaccine trial fails BioNTech stopped a Phase 2 mRNA cancer vaccine trial for colorectal cancer due to futility, and shares fell 10%. The failure contrasts with Moderna's success and reminds investors that most cancer vaccine attempts still fail, so pipeline risk remains high.

    This is the period's biggest company-specific negative event and directly answers why the stock moved.

  • Competition and cash define the outlook Moderna's win increases competition in personalized cancer vaccines, but BioNTech still holds €16.6 billion in cash and securities. Upcoming data at ESMO in October and a head and neck cancer interim analysis are the next catalysts that could restore or further dent confidence.

    It gives the balanced counterweight: competitive pressure versus financial strength and upcoming catalysts.

July 2026
▲2▼2

BioNTech's cancer push grows, but COVID decline and patent suits weigh

  • Cancer pipeline advances BioNTech's mRNA cancer vaccines and personalized immunotherapies are gaining recognition, and its jointly developed drug pumitamig is being tested in a new kidney cancer trial. These moves support future revenue potential beyond COVID, which could lift the stock as investors bet on long-term growth.

    Shows new progress in BioNTech's key growth area, oncology, which is central to its future value.

  • Takeover interest and strong cash BioNTech is seen as a potential acquisition target due to its €16.8 billion in cash and a pipeline with over 25 mid- to late-stage trials. A buyout could offer a premium to the current share price, though any deal is speculative and not guaranteed.

    Highlights a possible catalyst that could significantly boost the stock if a takeover materializes.

  • COVID revenue collapse forces restructuring BioNTech is exiting German manufacturing sites and selling its peptide unit as COVID vaccine demand plunges, with revenue falling from $21.6 billion in 2021 to $3.4 billion in 2025. This reflects the loss of its main revenue source and adds uncertainty, pressuring the stock.

    Directly explains a major negative force: the sharp decline in BioNTech's core COVID business and its cost-cutting response.

  • New patent lawsuits over COVID vaccine Arbutus and Roivant have filed international patent suits against Pfizer and BioNTech over lipid nanoparticle technology used in Comirnaty, seeking injunctions and damages. This adds legal risk and potential financial liability, which could weigh on the stock.

    Represents a fresh legal threat that could result in significant costs or restrictions on a key product.

▲2▼2

BioNTech's cancer push grows, but COVID decline and patent suits weigh

  • Cancer pipeline advances BioNTech's mRNA cancer vaccines and personalized immunotherapies are gaining recognition, and its jointly developed drug pumitamig is being tested in a new kidney cancer trial. These moves support future revenue potential beyond COVID, which could lift the stock as investors bet on long-term growth.

    Shows new progress in BioNTech's key growth area, oncology, which is central to its future value.

  • Takeover interest and strong cash BioNTech is seen as a potential acquisition target due to its €16.8 billion in cash and a pipeline with over 25 mid- to late-stage trials. A buyout could offer a premium to the current share price, though any deal is speculative and not guaranteed.

    Highlights a possible catalyst that could significantly boost the stock if a takeover materializes.

  • COVID revenue collapse forces restructuring BioNTech is exiting German manufacturing sites and selling its peptide unit as COVID vaccine demand plunges, with revenue falling from $21.6 billion in 2021 to $3.4 billion in 2025. This reflects the loss of its main revenue source and adds uncertainty, pressuring the stock.

    Directly explains a major negative force: the sharp decline in BioNTech's core COVID business and its cost-cutting response.

  • New patent lawsuits over COVID vaccine Arbutus and Roivant have filed international patent suits against Pfizer and BioNTech over lipid nanoparticle technology used in Comirnaty, seeking injunctions and damages. This adds legal risk and potential financial liability, which could weigh on the stock.

    Represents a fresh legal threat that could result in significant costs or restrictions on a key product.

Amgen Inc (AMGN)

Q3 2026
▲2▼2

Amgen Q3: Pelacarsen Blow Sinks Shares, Recalls and Rival Threats Weigh

  • Pelacarsen failure casts doubt on Amgen's olpasiran Novartis' heart drug pelacarsen failed, and because Amgen's similar olpasiran works the same way, investors feared it could fail too. Shares fell about 10% and BMO downgraded the stock.

    This was the single most severe event of the quarter, directly sinking the share price.

  • Court blocks Colorado's 70% Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, reducing regulatory risk for Amgen's biggest drug. This removes a threat that could have slashed revenue from a key product.

    A major legal win that eased a key overhang on the stock.

  • Q2 beat and raised guidance, key products grow 26% Amgen's Q2 earnings and revenue beat estimates, and the company raised its full-year guidance. Six key products grew 26%, showing the new drug lineup is driving growth.

    Strong financial results and raised outlook support the stock.

  • Recalls, competition, pipeline setback, cyberattack Corlanor and Sensipar recalls raised quality concerns. Merck's cheaper oral PCSK9 threatens Repatha, Sotyktu may erode Otezla, AMG 513 was discontinued, and a cyberattack triggered lawsuits.

    Multiple negative events that weighed on sentiment and future growth prospects.

September 2026
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

Latest
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

August 2026
▲2▼2

Amgen beats Q2, raises guidance, but obesity setback and cyberattack weigh

  • Q2 earnings beat and guidance raise Amgen reported Q2 adjusted EPS of $6.29 and revenue of $10.05B, beating estimates, and raised its 2026 guidance. Six key growth products grew 26%, reducing reliance on older drugs.

    This is a new positive fundamental development that directly supports the stock.

  • Repatha and Tezspire clinical wins Repatha cut death risk by 20% in a major heart trial, and Tezspire met all goals in an eosinophilic esophagitis study. These results lifted shares to a 52-week high and prompted analyst target hikes.

    New clinical data and analyst reactions are key drivers of the stock's move this period.

  • Obesity drug AMG 513 discontinued Amgen discontinued its obesity drug AMG 513, leaving MariTide trailing Eli Lilly and Novo Nordisk in the lucrative obesity market. This raises concerns about Amgen's competitive position.

    This is a new negative event that affects future growth prospects.

  • Cyberattack and drug-price pressure A July cyberattack exposed patient and proprietary data, triggering a class action investigation. Also, a looming US drug-price agreement with mid-sized biotechs could pressure Medicaid revenue.

    These are new risk factors that emerged during the period and could weigh on the stock.

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

  • Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.

    This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.

  • Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.

    New positive trial results expand a key product's potential, a fresh catalyst for the stock.

  • US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.

    This is a new regulatory risk that could directly affect Amgen's pricing and profits.

  • Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.

    This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

  • Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.

    This is the main new positive event that drove the stock up over 5% this period.

  • Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.

    It explains the underlying strength behind the earnings beat and why the stock rose.

  • Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.

    It is a new negative event that could pressure the stock and is important for a balanced view.

  • Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.

    It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 2026
▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

Q2 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

June 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

© 2026 MarketIVWhy